Bigal Marcelo E, Krymchantowski Abouch V, Hargreaves Richard
Merck Research Laboratories, Whitehouse Station, NJ 08889, USA.
Expert Rev Neurother. 2009 May;9(5):649-59. doi: 10.1586/ern.09.15.
The migraine-specific triptans have revolutionized the treatment of migraine and are currently the drugs of choice to treat a migraine attack in progress. Over the past 15 years, triptans were released in rapid succession, with each one demonstrating some specific pharmacokinetic properties that may be translated into clinical advantages. Triptans share many similarities, but also have important differences from one another. Accordingly, herein we discuss the class of the triptans. We first define the trigeminovascular system and its importance in migraine pain, then discuss the mechanism of action of the triptans and contrast the evidence supporting the use of different triptans. We close with our view of the future and hopes for the next generation of antimigraine therapies.
偏头痛特异性曲坦类药物彻底改变了偏头痛的治疗方式，目前是治疗正在发作的偏头痛的首选药物。在过去15年里，曲坦类药物相继快速推出，每一种都展现出一些可能转化为临床优势的特定药代动力学特性。曲坦类药物有许多相似之处，但彼此之间也存在重要差异。因此，在此我们讨论曲坦类药物类别。我们首先定义三叉神经血管系统及其在偏头痛疼痛中的重要性，然后讨论曲坦类药物的作用机制，并对比支持使用不同曲坦类药物的证据。最后我们阐述对未来的看法以及对下一代抗偏头痛疗法的期望。
